List view / Grid view
The FDA has approved Imfinzi for the treatment of patients with stage III non-small cell lung cancer whose tumours are not able to be surgically removed and whose cancer has not progressed after treatment...
International researchers believe that their new blood and urine tests which search for damage to proteins are the first of their kind to detect early autism spectrum disorders...
Alzheimer's drug appears to reverse structural and genetic brain changes that affect memory and learning...
An MRI technique that requires no contrast agent, combined with sophisticated data analysis, could reduce the number of unnecessary breast biopsies...
Clinical trial shows treatment is effective for children with spinal muscular atrophy...
Study is the first 'prevention of infection' trial conducted for tuberculosis, the world's leading infectious disease killer...
An antibody used to treat the skin disease psoriasis is also effective at reducing aortic inflammation, a key marker of future risk of major cardiovascular events...
A technique which allows the continuous production and collection of a cell has been developed removing the limit on the number of cells that can be grown in a culture dish...
In order to support the continued growth of our business in North America, FPS opened a new office in Philadelphia, PA and appointed Frederic Le Pape as General Manager...
New research indicates that women with asthma who only use short-acting asthma relievers take longer to become pregnant than other women...
NICE has issued its final appraisal decision recommending reimbursement of Lenvima for the treatment of progressive, locally advanced or metastatic, differentiated thyroid carcinoma...
Hapa Ink is a division of Hapa, the innovative on demand printing specialist. It is experiencing a rapid increase in demand of sales for individually developed inks...
Wickham Laboratories Ltd will exhibit on Stand 408 at the Making Pharmaceuticals Europe Conference, from the 13 - 14 March 2018 in Belgium at Brussels Expo centre...
Novartis and the Bill & Melinda Gates Foundation have formed an alliance to advance the development of Novartis' drug candidate KDU731...
NEWARK, Del. – W.L. Gore & Associates, Inc. (“Gore”), a global materials science company, will introduce its new GORE™ ImproJect™ Plunger at Pharmapack 2018, Europe's dedicated pharmaceutical packaging and drug delivery event. Gore will be in Booth A12 at the exhibition, to be held February 7 and 8, 2018, at…
